Utsunomiya, Japan
Utsunomiya, Japan

Teikyo University is a private university headquartered in the Itabashi ward of Tokyo, Japan. It was established in 1931 as Teikyo Commercial High School . It became Teikyo University in 1966. It is part of Teikyo Group, a multinational educational foundation that also operates language and cultural exchange facilities at pre-university levels in various countries.The university consists of eight undergraduate facilities, one junior college, and six graduate schools. Five main campuses in Japan are supplemented by several overseas campuses that provide study-abroad opportunities for Japanese students, as well as Japanese-oriented learning for residents of the campuses' home countries. Total enrollment is about 20,000 students. Although the headquarters is the Itabashi campus, the majority of students are enrolled at the Hachiōji campus in West Tokyo. Wikipedia.


Time filter

Source Type

Patent
Teikyo University and Uha Mikakuto Co. | Date: 2015-05-28

There are provided an oral composition and a confection that exhibit activity equivalent to or higher than that of a decanoic acid-containing composition, and a method for producing such an oral composition. The oral composition and the confection contain at least three ingredients: cinnamon, low molecular proanthocyanidin, and menthol. The method for producing, the oral composition includes the steps of: dissolving at least 0.2 to 1.0% by weight of low molecular proanthocyanidin in 0.2 to 2.0% by weight of at least one water-soluble solvent selected from glycerin or propylene glycol to form a solution; kneading at least 0.1 to 0.5% by weight of cinnamon and 0.1 to 0.4% by weight of menthol into sugar-free base dough to prepare candy- or gel-like kneaded dough; and mixing the solution with the kneaded dough.


Patent
Teikyo University and Gc Corporation | Date: 2013-05-15

Provided is a treatment method which enables regeneration of bone tissue even when the size of a damaged site of bone is large. The treatment method comprises the steps of: culturing chondrocytes which have been seeded onto a porous body, or differentiating stem cells having chondrogenic differentiation potential which have been seeded onto a porous body into chondrocytes and culturing the chondrocytes; and implanting the porous body having the cultured chondrocytes.


Rock K.L.,UMass Medical School | Lai J.-J.,UMass Medical School | Kono H.,Teikyo University
Immunological Reviews | Year: 2011

The immune system plays an essential role in protecting the host against infections and to accomplish this task has evolved mechanisms to recognize microbes and destroy them. In addition, it monitors the health of cells and responds to ones that have been injured and killed, even if this occurs under sterile conditions. This process is initiated when dying cells expose intracellular molecules that can be recognized by cells of the innate immune system. As a consequence of this recognition, dendritic cells are activated in ways that help to promote T-cell responses to antigens associated with the dying cells. In addition, macrophages are stimulated to produce the cytokine interleukin-1 that then acts on radioresistant parenchymal cells in the host in ways that drive a robust inflammatory response. In addition to dead cells, a number of other sterile particles and altered physiological states can similarly stimulate an inflammatory response and do so through common pathways involving the inflammasome and interleukin-1. These pathways underlie the pathogenesis of a number of diseases. © 2011 John Wiley & Sons A/S.


Patent
Teikyo University, Hokkaido University and Adeka Corporation | Date: 2013-04-10

The object of the present invention is to provide a biomarker which is highly correlated to the conventional biomarkers of metabolic syndrome or life-style related disease in a wide range of subjects to be tested, including subjects of special health check-up aged between 40 and 74, or an advantageous method for detecting metabolic syndrome or life-style related disease. The object can be solved by a method for detecting metabolic syndrome or life-style related disease characterized by comprising the step of measuring the concentration of choline plasmalogen in a sample to be tested.


Yamaoka K.,Teikyo University | Tango T.,Center for Medical Statistics
BMC Medicine | Year: 2012

Background: To evaluate the effect of lifestyle modifications on metabolic syndrome (MetS) as assessed by its resolution and improved values for its components.Methods: This was a systematic review and meta-analysis. Searches were performed of MEDLINE and the Cochrane Database from January 1966 to October 2011 to identify randomized controlled trials (RCTs) related to the study objective. The included studies were RCTs restricted to the English language, with a follow-up period of 6 months or more, which reported overall resolution of MetS or values of MetS components (fasting blood glucose, waist circumference, high-density lipoprotein (HDL), triglycerides, and systolic and diastolic blood pressure (SBP, DBP)). Two investigators independently assessed study eligibility. The effect sizes were the relative proportion of patients with resolved MetS and mean differences in MetS component values from baseline to 1-year follow-up in a lifestyle-modification intervention (LMI) group versus a control (conventional lifestyle education or no treatment) group. Meta-analyses were conducted using a random-effects model.Results: Eleven interventions in eight RCTs were used for the meta-analyses. The relative proportion of patients with resolved MetS in the intervention group was approximately 2.0 (95% CI 1.5 to 2.7) times greater in the intervention group compared with the control group (7 interventions, n = 2.839). LMI (5 interventions, n = 748) significantly reduced mean values for SBP by -6.4 mmHg (95% CI -9.7 to -3.2), DBP by -3.3 mmHg (95% CI -5.2 to -1.4), triglycerides by -12.0 mg/dl (95% CI -22.2 to -1.7), waist circumference by -2.7 cm (95% CI -4.6 to -0.9), and fasting blood glucose by -11.5 mg/dl (95% CI -22.4 to -0.6) (5 interventions), but reductions were not significant for HDL (1.3 mg/dl; 95% CI -0.6 to 3.1).Conclusions: The LMI was effective in resolving MetS and reducing the severity of related abnormalities (fasting blood glucose, waist circumference, SBP and DBP, and triglycerides) in subjects with MetS. © 2012 Yamaoka and Tango; licensee BioMed Central Ltd.


Teramoto T.,Teikyo University
Expert Opinion on Pharmacotherapy | Year: 2012

Introduction: Statins are currently the most effective drugs for lowering low-density lipoprotein cholesterol (LDL-C) and represent the first choice for treating hypercholesterolemia. Pitavastatin was launched as a new statin on the Japanese market in 2003, followed by Korea, Thailand, China, the United States and Europe. This review summarizes and evaluates new insights into pitavastatin, from clinical trials since 2010. Areas covered: This article reviews studies that compare pitavastatin with various other statins: i) Randomized Head-to-Head Comparison of Pitavastatin, Atorvastatin, and Rosuvastatin for Safety and Efficacy (Quantity and Quality of LDL): the PATROL Trial; ii) various Phase III clinical trials in Western countries; iii) The Comparison of Preventive Effect on Cardiovascular Events With Different Statins (CIRCLE) study; and iv) The Livalo Effectiveness and Safety (LIVES) Study Extension. Pitavastatin was found to have a similar LDL-C-lowering effect to other strong statins but also had a strong HDL-C-elevating effect and did not worsen glucose metabolism. Expert opinion: Pitavastatin has been launched in various countries around the world as a statin with potent LDL-C-lowering activity that is virtually unmetabolized by the cytochrome P450 family, with relatively few drugdrug interactions and no adverse effects on blood glucose. Pitavastatin thus appears well suited to long-term use. © 2012 Informa UK, Ltd.


Yamane H.,Teikyo University
Bioscience, Biotechnology and Biochemistry | Year: 2013

We performed extensive functional characterization of diterpenoid phytoalexin biosynthetic genes in rice, and found that the genes for the biosynthesis of the major diterpenoid phytoalexins, phytocassanes and momilactones, are clustered on chromosomes 2 and 4, and that their expression is coordinately induced in rice cells after elicitation. Isopentenyl diphosphate, an early precursor of diterpenoid phytoalexins, was found to be synthesized through the plastidic methylerythritol phosphate pathway. We also found that chitin elicitor receptor kinase OsCERK1 and a mitogen-activated protein kinase cascade, the OsMKK4-OsMPK6 cascade, play essential roles in the elicitor-induced production of diterpenoid phytoalexins. In addition, a basic leucine zipper transcription factor, OsTGAP1, was identified as a key regulator of the coordinated expression of the clustered genes and the methylerythritol phosphate pathway genes. Naringenin 7-O-methyltransferase (OsNOMT) was also identified as a key enzyme in the biosynthesis of another major rice phytoalexin, sakuranetin.


Watabe M.,Teikyo University | Nakaki T.,Teikyo University
Journal of Cell Science | Year: 2011

Misfolded protein aggregates elicit a stress response, and their clearance is crucial for cell survival. These aggregates are transported by cytoplasmic deacetylase HDAC6 and dynein motors to the aggresome via the microtubule network, and are removed by autophagic degradation. HDAC6 activity is necessary for both the transport and clearance of protein aggregates. However, the cellular factors that regulate HDAC6 activity remain unknown. Here we show that protein kinase CK2 is a crucial modulator of HDAC6 activity because CK2 directly phosphorylates HDAC6 and increases cytoplasmic deacetylase activity. Indeed, cells that expressed HDAC6 mutated at Ser458, a CK2-mediated phosphorylation site, failed to both form and clear aggresomes, and increased cytotoxicity. Interestingly, Ser458 is conserved only in higher primates, such as human and chimpanzee, but not in the rhesus macaque. These findings identify CK2 as a crucial protein involved in the formation and clearance of aggresomes, and hence in cell viability in response to misfolded protein stress. © 2011. Published by The Company of Biologists Ltd.


Nomura K.,Teikyo University | Yamanouchi T.,Teikyo University
Journal of Nutritional Biochemistry | Year: 2012

Nonalcoholic fatty liver disease (NAFLD) currently affects 20%-30% of adults and 10% of children in industrialized countries, and its prevalence is increasing worldwide. Although NAFLD is a benign form of liver dysfunction, it can proceed to a more serious condition, nonalcoholic steatohepatitis (NASH), which may lead to liver cirrhosis and hepatocellular carcinoma. NAFLD is accompanied by obesity, metabolic syndrome and diabetes mellitus, and evidence suggests that fructose, a major caloric sweetener in the diet, plays a significant role in its pathogenesis. Inflammatory progression to NASH is proposed to occur by a two-hit process. The first "hit" is hepatic fat accumulation owing to increased hepatic de novo lipogenesis, inhibition of fatty acid beta oxidation, impaired triglyceride clearance and decreased very-low-density lipoprotein export. The mechanisms of the second "hit" are still largely unknown, but recent studies suggest several possibilities, including inflammation caused by oxidative stress associated with lipid peroxidation, cytokine activation, nitric oxide and reactive oxygen species, and endogenous toxins of fructose metabolites. © 2012 Elsevier Inc.


Patent
Teikyo University | Date: 2015-09-30

The present invention provides novel medical means to facilitate glutathione (GSH) synthesis in the brain. These means are miR-96-5p inhibitor increasing GSH expression in the brain and a pharmaceutical composition comprising the miR-96-5p inhibitor and having a preventive and/or therapeutic performance to a disease caused by decrease of GSH amount or depression of GSH activity.

Loading Teikyo University collaborators
Loading Teikyo University collaborators